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Widening the options for recurrent malaria
The global need for new antimalarial drugs and new 
combinations is enormous and urgent,1,2 but their 
successful delivery needs resilience to overcome the 
barriers imposed by expensive and lengthy clinical 
development plans. Attention is often directed to 
areas such as southeast Asia, where some antimalarial 
combinations are failing but transmission intensities 
are much lower than in sub-Saharan African countries. 
Children in Africa have frequent and life-threatening 
malaria infections as they grow up, and these need to be 
treated safely.
Pyronaridine–artesunate and dihydroartemisinin–
piperaquine are two artemisinin combination therapies 
(ACTs) that exemplify the challenges that arise in the 
pathway towards licensure and wider implementation. 
These two drug combinations have a good track 
record of efficacy3,4 and are approved by the European 
Medicines Agency (EMA). However, their introduction 
into first-line therapies in malaria-endemic countries, 
particularly in sub-Saharan Africa where the global 
malaria problem is worst, has been sporadic and slow. 
Questions about the safety of ACTS (ie, hepatotoxicity 
for pyronaridine–artesunate and cardiotoxicity for 
dihydroartemisinin–piperaquine) might have delayed 
their endorsement by WHO,5 thereby obstructing 
adoption into national malaria-control programmes. 
They are also needed in southeast Asia where other 
antimalarial treatments are no longer effective when 
used in conventional doses.6
Adequate assessment of antimalarial drugs should 
not be restricted to investigating their ability to cure a 
single infection safely, but to rather account for their 
overall efficacy in decreasing the long-term cumulative 
incidence of disease and their prolonged safety when 
used repeatedly. In high-transmission, malaria-endemic 
areas, repeated symptomatic malaria infections are 
common until the acquisition of a degree of immunity 
against the disease. In highly endemic vivax transmission 
areas, relapses caused by hypno zoites frequently 
contribute to repeated clinical episodes of malaria. 
In The Lancet, Issaka Sagara and colleagues from the 
West African Network for Clinical Trials of Antimalarial 
and patient can both agree on an individualised action 
plan aimed at adjusting therapy to minimise any clearly 
visible low or high glucose patterns, which should result 
in more glucose values that are in the target range. 
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Drugs (WANECAM) provide reassuring results on the 
safety and efficacy of pyronaridine–artesunate and 
dihydroartemisinin–piperaquine in a large, randomised, 
controlled trial undertaken in Mali, Burkina Faso, and 
Guinea.7 For 2 years they followed up a longitudinal 
cohort of 4710 adult and paediatric patients aged 
6 months and older with microscopically confirmed 
Plasmodium spp malaria to assess the safety and efficacy 
of pyronaridine–artesunate and dihydroartemisinin–
piperaquine to treat recurrent malaria versus current 
recommended first-line (re)treatments with artemether–
lumefantrine or artesunate–amodiaquine. All treatments 
were once-daily or twice-daily tablets or granules given 
orally over 3 days at the study centres, and patients were 
followed up as outpatients up to day 42.
The results of this large and complex trial7 confirmed 
the non-inferiority of both pyronaridine–artesunate 
and dihydroartemisinin–piperaquine against the com-
parators for the primary endpoints of (1) 2-year malaria 
incidence rate in the intention-to-treat population 
(pyronaridine–artesunate vs artemether–lume fantrine 
[1·77, 95% CI 1·63–1·93 vs 1·87, 1·72–2·03; rate ratio 
(RR) 1·05, 95% CI 0·94–1·17] and vs artesunate–
amodiaquine [1·39, 95% CI 1·22–1·59 vs 1·35, 1·18–1·54; 
RR 0·97, 0·87–1·07]; dihydroartemisinin–piperaquine vs 
artemether–lumefantrine [1·16, 95% CI 1·01–1·34 vs 1·42, 
1·25–1·62; RR 1·22, 95% CI 1·06–1·41] and vs artesunate–
amodiaquine [1·35, 1·21–1·51 vs 1·68, 1·51–1·88; RR 1·25, 
1·02–1·50]); and (2) adequate clinical and parasitological 
response in uncomplicated malaria across all episodes 
assessed in the per-protocol population on days 28 and 42 
(for P falciparum malaria, PCR-adjusted adequate clinical 
and parasitological response was greater than 99·5% at 
day 28 and greater than 98·6% at day 42 for all ACTs).
These findings highlight that all four ACTs are robust 
in some of the highest pockets of malaria transmission 
globally and they exemplify the cumulative advantages 
of using drug combinations that include partner drugs 
with longer elimination half-lives, such as piperaquine 
(around 4 weeks in dihydroartemisinin–piperaquine) or 
pyronaridine (10–13 days in pyro naridine–artesunate). 
Indeed, the crude effects of dihydroartemisinin–
piperaquine on the 2-year incidence of malaria 
compared with artemether–lumefantrine or artesunate–
amodiaquine probably reflect the better long-term and 
cumulative effects of post-treatment prophylaxis with 
piperaquine in preventing new infections, a finding that 
has implications for the current malaria-elimination 
agenda.8
Additionally, the WANECAM study7 confirmed the 
good tolerability of single and repeated treatments 
of pyronaridine–artesunate and dihydroartemisinin–
piperaquine. For pyronaridine–artesunate, this finding 
ratifies the revision in 20159 of the initial 2012 EMA 
approval,10 which originally limited the treatment 
possibilities both individually (to just once in a lifetime) 
and geographically (to low-endemic settings with 
high risk of artemisinin resistance). The 2015 revision 
has removed all restrictions on repeat dosing, on use 
only in areas of high resistance and low transmission, 
and on requirements for liver function monitoring. 
The results from the WANECAM study7 should enable 
rapid inclusion of pyronaridine–artesunate into WHO’s 
malaria treatment guidelines.5
The WANECAM trial did confirm an increased risk of 
liver transaminitis in some recipients of pyronaridine–
artesunate. However, the absence of any clinical 
implication, the transient nature of the increases in all 
cases, and the absence of an incremental effect in those 
receiving repeated doses are reassuring, and support the 
wider use of pyronaridine–artesunate for the treatment 
of malaria. The safety of pyronaridine–artesunate 
should continue to be monitored, including its use in 
HIV-infected individuals, as this particularly vulnerable 
population was excluded from participating in the 
trial—an important limitation for the generalisation of 
the results. A large study of pyronaridine–artesunate 
in which HIV infection is not an exclusion criterion is 
ongoing (NCT03201770).
The WANECAM trial also shed light on other safety 
concerns, particularly prolongation of the QT interval 
and the consequent increased risk of life-threatening 
arrhythmias. The findings suggested that the incidence of 
QTcF prolongation was higher after dihydroartemisinin–
piperaquine versus artemether–lumefantrine and 
pyronaridine–artesunate, but no differences were noted 
between dihydroartemisinin–piperaquine and artesunate–
amodiaquine. There were no clinical symptoms or 
complications associated with the prolongation, and 
retreatment did not seem to make these findings worse, 
although the numbers studied were small.
Manufacturers recommend that dihydroartemisinin–
piperaquine should be taken under fasting conditions to 
minimise the risks of a food effect that increases plasma 
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Universal health coverage (UHC) has assumed an iconic 
place in work to achieve the Sustainable Development 
Goals (SDGs). Its central importance for achieving 
SDG 3—ensuring healthy lives for all—is proven by 
the increasingly sophisticated efforts to measure 
UHC and to estimate to what extent UHC can be 
achieved by 2030. An example is the Global Burden of 
Disease (GBD).1 The GBD team constructed a UHC Index 
by beginning with the idea of access to quality essential 
health-care services and access to safe, effective, quality, 
and affordable essential medicines and vaccines. They 
then took a collection of tracer indicators, including 
for vaccines, antenatal care, skilled birth attendance, 
facility births, antiretroviral coverage, and treatments 
for several diseases amenable to personal health care. 
The GBD’s UHC Index was based on a comprehensive 
assessment of these components. Palliative care and 
pain relief were not among these measures.
Palliative care and pain relief are some of the most 
neglected dimensions of global health today. They are 
A milestone for palliative care and pain relief
concentrations of piperaquine and cardiac effects. In the 
WANECAM study,7 dihydroartemisinin–piperaquine was 
administered without first imposing a fast, providing 
further reassurance about safety. The results from this 
study are also consistent with the opinions of an expert 
panel convened by WHO to review the cardiotoxicity 
of antimalarial drugs,11 and with the conclusions of a 
meta-analysis reviewing the safety of repeated use of 
dihydroartemisinin–piperaquine.12 They further support 
the continued use of dihydroartemisinin–piperaquine in 
malaria-endemic areas.
Rigorous safety assessments of any new drug are 
necessary to safeguard patients. Generally, risk–benefit 
analyses of antimalarial drugs also need to account for 
the life-threatening potential and continuing morbidity 
associated with malaria. The findings from the WANECAM 
study support upscaling the use of pyronaridine–
artesunate and dihydroartemisinin–piperaquine in sub-
Saharan Africa so that they can contribute even more 
effectively to the global fight against malaria.
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